Guideline for Switching from Argatroban to Fondaparinux in Heparin‑Induced Thrombocytopenia (HIT)

Timing of the Switch

• Switch to fondaparinux only after platelet count has recovered to > 150 × 10⁹/L; premature discontinuation of argatroban (< 5 days of therapy) is associated with a 70 % rate of thrombotic adverse events during warfarin transition【1】.
• Adequate platelet recovery is essential because the heightened thrombotic risk in HIT persists for 2–4 weeks after treatment initiation【1】.

Dosing and Administration of Fondaparinux

• Use therapeutic, weight‑based dosing: 5 mg subcutaneously once daily for patients < 50 kg, 7.5 mg once daily for 50–100 kg, and 10 mg once daily for > 100 kg【2】.
• Prophylactic dosing is insufficient for HIT treatment【2】.
• Fondaparinux is administered subcutaneously once daily, eliminating the need for continuous infusion【2】.

Renal Function Considerations

• Fondaparinux is contraindicated when creatinine clearance is < 30 mL/min because it is eliminated exclusively by the kidneys【2】.
• In patients with severe renal impairment, continue argatroban (hepatically metabolized) rather than switching to fondaparinux【4】【3】【5】.
• Reports of hemorrhage associated with fondaparinux use in renal failure, especially after cardiac surgery, underscore the renal safety restriction【2】.

Monitoring During Argatroban Therapy (Pre‑Switch)

• Target aPTT 1.5–3 × baseline, not exceeding 100 seconds【6】【5】.
• Obtain the first aPTT measurement 2–3 hours after infusion start (steady state reached in 1–3 hours)【6】【5】.
• Perform at least one daily aPTT check while on argatroban【6】.
• In settings with baseline prolonged aPTT (e.g., ICU, post‑cardiac surgery, liver failure), aPTT monitoring may be unreliable【6】【5】.
• Consider alternative assays—ecarin clotting time or diluted thrombin time (target 0.5–1.5 mg/mL)—for more accurate monitoring in complex cases【5】【4】.

Advantages of Fondaparinux Over Continuing Argatroban

• No cross‑reactivity with anti‑PF4 antibodies, unlike danaparoid【2】.
• Does not alter aPTT or INR, simplifying subsequent warfarin transition【1】【2】.
• No requirement for specific bioassay monitoring【2】.
• Lower drug acquisition cost compared with danaparoid or argatroban【2】.

Patient Selection for Fondaparinux

• Appropriate for stable patients without severe renal or hepatic impairment and without active bleeding risk【7】【4】.
• Should be avoided in unstable patients, those with life‑threatening thrombosis, or those in intensive care; argatroban remains the preferred agent in these scenarios【7】【4】.
• Suitable for patients without significant comorbidities or recent/planned invasive procedures【7】.

Duration of Therapy and Transition to Oral Anticoagulation

• Continue anticoagulation for ≥ 4 weeks in isolated HIT (no thrombosis)【1】.
• Extend therapy to ≈ 3 months when HIT is complicated by thrombosis (HITT), aligning with treatment of provoked venous thromboembolism【1】.
• Fondaparinux facilitates transition to warfarin because it does not interfere with INR measurements【1】【2】.

Critical Pitfalls to Avoid

• Do not discontinue argatroban solely based on an elevated INR; argatroban artificially raises INR, and 21 % of patients with INR > 3.0 had sub‑therapeutic INR four hours after stopping argatroban【1】.
• Switching to fondaparinux eliminates this pitfall, as fondaparinux has no effect on INR【2】.
• Never use fondaparinux in patients with creatinine clearance < 30 mL/min due to renal elimination and heightened bleeding risk【2】.